Aileron Therapeutics (ALRN) Revenue & Revenue Breakdown
Aileron Therapeutics Revenue Highlights
Aileron Therapeutics Revenue by Period
Aileron Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | - |
Aileron Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $134.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | - |
Aileron Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CTMX | CytomX Therapeutics | $101.21M | $25.11M |
CRIS | Curis | $10.02M | $2.55M |
ASMB | Assembly Biosciences | $7.16M | $5.79M |
HSTO | Histogen | $3.77M | $5.00K |
SABS | SAB Biotherapeutics | $2.24M | $263.14K |
CBIO | Gyre Therapeutics | $794.00K | - |
VCNX | Vaccinex | $570.00K | $232.00K |
MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
ABVC | ABVC BioPharma | $152.43K | $117.14K |
BNTC | Benitec Biopharma | $75.00K | $6.00K |
APTX | Aptinyx | - | - |
BPTH | Bio-Path | - | - |
EVLO | Evelo Biosciences | - | - |
TIL | Instil Bio | - | - |
ALRN | Aileron Therapeutics | - | - |
FWBI | Entero Therapeutics | - | - |
NLTX | Neurogene | - | - |
GOVX | GeoVax Labs | - | - |
ARTL | Artelo Biosciences | - | - |
NUVB | Nuvation Bio | - | $1.44M |
SLRX | Salarius Pharmaceuticals | - | - |
ALRN Revenue FAQ
What is Aileron Therapeutics’s yearly revenue?
Aileron Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ALRN's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Aileron Therapeutics’s quarterly revenue?
Aileron Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ALRN's quarterly revenue for Q4 2023 was $134K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Aileron Therapeutics’s revenue growth rate?
Aileron Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.